Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis
Yongning Pan, Fanfan Song, Xuehua Liu, Yan Zhang, Juanjuan Zhang, Guangyao Song, Luping Ren · 2026
Read Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis by Yongning Pan, Fanfan Song, Xuehua Liu, Yan Zhang, Juanjuan Zhang, Guangyao Song, Luping Ren (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13459454.txt.
Description
Yongning Pan and co-authors traced how the diabetes drug tirzepatide improves fatty liver disease in mice, focusing on an inflammation signal called the CCL2/CCR2 axis. The condition, metabolic dysfunction associated steatotic liver disease, combines liver fat with metabolic problems. In their 2026 experiment, thirty two mice were split into four groups: control, high fat diet, diet plus semaglutide, and diet plus tirzepatide. Liver tissue underwent gene expression and protein profiling to map the drug's footprint.
The rich diet produced high blood sugar, insulin resistance, raised liver enzymes, and heavy liver fat with inflammation. Both drugs reversed much of this damage. Tirzepatide additionally lowered the liver to body weight ratio and cut liver levels of inflammatory molecules including MCP-1, IL-1beta, and TNF-alpha, while partly restoring the calming signal IL-10. The profiling pointed to the CCL2/CCR2 recruitment pathway as a key route of benefit.
Catalog record
| CREATOR | Yongning Pan, Fanfan Song, Xuehua Liu, Yan Zhang, Juanjuan Zhang, Guangyao Song, Luping Ren |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |